In the third week of May, K-beauty leader Dalba Global, valued at 800 billion won, will kick off its general subscription for listing on the securities market. Alongside Dalba, several biotech companies are advancing with their KOSDAQ listing processes, signaling a busy month for the South Korean stock exchange.
According to industry sources, Rocket Healthcare, a long-term regeneration platform company, is poised to debut on the KOSDAQ on May 12. The company, which specializes in bioink production, automated modeling for affected areas, and medical 3D bioprinter technology, currently has supply contracts in 46 countries. By 2027, Rocket aims to expand its commercialization efforts to 72 countries and explore new markets such as skin cancer, cartilage, and kidney treatments. Post-listing, 36.3% of the company’s shares will be available for circulation.
Dalba Global, known for its popular beauty product “Crew Mist,” will begin its two-day subscription period for KOSPI listing from May 9 to May 12. The company’s First Spray Serum has accumulated over 50 million bottles in sales, contributing to a first-quarter revenue of 113.8 billion won and an operating profit of 30.1 billion won—up 72% and 104%, respectively, compared to the same period last year. Despite these impressive figures, Dalba’s anticipated public offering price is set at a price-earnings ratio (PER) 11 to 14 times lower than the average for cosmetics companies. After listing, the available share distribution will be 32.7%, with an increase to 68% after three months.
Meanwhile, biotech company Intussell, known for its ADC platform technology, is set for a general subscription from May 13 to May 14. Founded by Park Tae-kyo, former CTO of Rigachem Bio, Intussell has made strides in advancing the ADC platform technology. The company has entered into technology transfer agreements with Samsung Bioepis and ABL Bio, positioning itself as a key player in the competition to develop next-generation ADC treatments. Intussell aims to turn a profit by 2027 through new drug candidates and additional technology transfer agreements.
These developments reflect the continued growth of the K-beauty and biotech sectors, as Dalba Global and other companies prepare to expand their influence in the South Korean stock market.
Related topics:
